XM无法为美国居民提供服务。
E
E

EXACT

技术摘要

指标价值趋势
指标价值趋势
指标价值趋势
指标S3S2S1PR1R2R3

市场新闻

U.S. Aerovironment, Insulet, Viasat

U.S. RESEARCH ROUNDUP- Aerovironment, Insulet, Viasat Sept 17 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Aerovironment, Insulet and Viasat, on Tuesday. HIGHLIGHTS * Aerovironment Inc AVAV.O : Raymond James cuts to market perform from outperform * Frontier Communications Parent Inc FYBR.O : JP Morgan cuts to neutral from overweight * Insulet Corp PODD.O : Piper Sandler raises target price to $285 from $230 * Relm
B
C
C
E
I
D

U.S. Cintas, Sprouts Farmers Market, Voya Financial

U.S. RESEARCH ROUNDUP-Cintas, Sprouts Farmers Market, Voya Financial Sept 12 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Cintas Corp, Sprouts Farmers market and Voya Financial, on Thursday. HIGHLIGHTS * Ally Financial Inc ALLY.N : RBC cuts target price to $40 from $49 * Cintas Corp CTAS.O : CFRA adjusts target price to $170 from $645 to reflect 4-for-1 stock split * Gilead GILD.O : Raymond James raises target pri
C
E
G
L
N
P
S
E
A
D
E
L

Exact Sciences Q2 Basic 0.09

BRIEF-Exact Sciences Q2 Basic EPS USD -0.09 Jul 31 (Reuters) - Exact Sciences Q2 revenue USD 699.264 million vs. IBES estimate USD 690 million. Q2 pretax profit USD -14.345 million vs. IBES estimate USD -54 million Q2 net income USD -15.808 million vs. IBES estimate USD -57.3 million Q2 income from operations USD -26.257 million
E

Exact Sciences Corp <EXAS.OQ> expected to post a loss of 32 cents a share - Earnings Preview

Exact Sciences Corp expected to post a loss of 32 cents a share - Earnings Preview Exact Sciences Corp EXAS.OQ EXAS.O is expected to show a rise in quarterly revenue when it reports results on July 31 for the period ending June 30 2024 The Madison Wisconsin-based company is expected to report a 10.9% increase in revenue to $690.003 million from $622.09 million a year ago, according to the mean estimate from 22 analysts, based on LSEG data.The company's guidance on May 8 2024, for the period en
E

Guardant's blood-based cancer test moves closer to Medicare coverage with FDA approval

UPDATE 4-Guardant's blood-based cancer test moves closer to Medicare coverage with FDA approval Adds CEO comments in paragraphs 5, 7; updates shares By Leroy Leo July 29 (Reuters) - Guardant Health GH.O said its blood test to detect cancer that starts in the colon or rectum got an approval from the U.S. Food and Drug Administration, with the test moving closer toward gaining coverage under the country's Medicare insurance program.
E

商品详情

热门商品

免责声明: XM Group仅提供在线交易平台的执行服务和访问权限,并允许个人查看和/或使用网站或网站所提供的内容,但无意进行任何更改或扩展,也不会更改或扩展其服务和访问权限。所有访问和使用权限,将受下列条款与条例约束:(i) 条款与条例;(ii) 风险提示;以及(iii) 完整免责声明。请注意,网站所提供的所有讯息,仅限一般资讯用途。此外,XM所有在线交易平台的内容并不构成,也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。

所有在线交易平台所发布的资料,仅适用于教育/资讯类用途,不包含也不应被视为用于金融、投资税或交易相关咨询和建议,或是交易价格纪录,或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。

本网站上由XM和第三方供应商所提供的所有内容,包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接,皆保持不变,并作为一般市场评论所提供,而非投资性建议。所有在线交易平台所发布的资料,仅适用于教育/资讯类用途,不包含也不应被视为适用于金融、投资税或交易相关咨询和建议,或是交易价格纪录,或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解,XM非独立投资研究提示和风险提示相关资讯,更多详情请点击 这里

风险提示: 您的资金存在风险。杠杆商品并不适合所有客户。请详细阅读我们的风险声明